Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American diabetes association and the European association for the study of diabetes

Diabetes Care

Volumn 29, Issue 8, 2006, Pages 1963-1972

  Nathan, David M ^a   Buse, John B ^b   Davidson, Mayer B ^c   Heine, Robert J ^d   Holman, Rury R ^e   Sherwin, Robert ^f   Zinman, Bernard ^g  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; CHLORPROPAMIDE; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; SULFONYLUREA DERIVATIVE;

ALGORITHM; BEHAVIOR MODIFICATION; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONSENSUS; DIARRHEA; DIET THERAPY; DRUG BINDING; DRUG EFFECT; DRUG SAFETY; EXERCISE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LACTIC ACIDOSIS; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; SIDE EFFECT; WEIGHT GAIN;

ALGORITHMS; DIABETES MELLITUS, TYPE 2; EUROPE; HUMANS; HYPERGLYCEMIA; SOCIETIES, MEDICAL; UNITED STATES;

EID: 33746588255     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-9912     Document Type: Conference Paper

References (76)

1. American Diabetes Association. Standards of medical care of diabetes. Diabetes Care 28 (Suppl. 1):S15-S35, 2005
2. European Diabetes Policy Group: A desktop guide to type 2 diabetes mellitus. Diabet Med 16:716-730, 1999
3. The Royal College of General Practitioners Effective Clinical Practice Unit: Clinical guidelines for type 2 diabetes mellitus: management of blood glucose [article online], 2002. Available from http://www.nice.org.uk/pdf/ NICE_full_blood_glucose.pdf
4. Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med 329:978-986, 1993
5. Reichard P, Nilsson B-Y, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-309, 1993
6. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
7. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
8. Ohkubo Y, Kishikawa H, Araki E, Takao M, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
9. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes. N Engl J Med 348:2294-2303, 2003
10. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653, 2005
11. Advance Collaborative Group: ADVANCE: Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabet Med 22:882-888, 2005
12. Bastien A: The ACCORD trial: a multidisciplinary approach to control cardiovascular risk in type 2 diabetes mellitus. Pract Diabetol 23:6-11, 2004
13. Nathan DM: Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 347:1342-1349, 2002
14. Deeg MA: Basic approach to managing hyperglycemia for the nonendocrinologist. Am J Cardiol 96 (Suppl. 1):37E-40E, 2005
15. Sheehan MT: Current therapeutic options in type 2 diabetes mellitus: a practical approach. Clin Med Res 1:189-200, 2003
16. Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes. JAMA 287:360-372, 2002
17. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL: Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 260:2864-2871, 1988
18. Chase HP, Jackson WE, Hoops, SL, Cockerham RS, Archer PG, O'Brien D: Glucose control and the renal and retinal complications of insulin-dependent diabetes. JAMA 261:1155-1160, 1989
19. American Diabetes Association: Standards of medical care in diabetes-2006. Diabetes Care 29 (Suppl. 1):S4-42, 2006
20. Little RR, Rohlfing CL, Wiedmeyer H-M, Myers GL, Sacks DB, Goldstein DE: The National Glycohemoglobin Standardization Program (NGSP): a five year progress report. Clin Chem 47:1985-1992, 2001
21. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
22. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Rocella EJ, the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure, the National High Blood Pressure Education Program Coordinating Committee: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560-2571, 2003
23. DCCT Research Group: The association between glycemic exposure and long-term diabetic complications in the Diabetes Control and Complications Trial. Diabetes 44:968-983, 1995
24. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
25. National Institutes of Health: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, MD, National Institutes of Health, 1999 (NIH publ. no. 98-4083)
26. Groop L: Sulfonylureas in NIDDM. Diabetes Care 15:737-747, 1992
27. Bailey CJ, Turner RC: Metformin. N Engl J Med 334:574-583, 1996
28. Malaisse WJ: Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat Endocrinol 2:401-414, 2003
29. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C: Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev CD003639, 2005
30. Genuth S: Insulin use in NIDDM. Diabetes Care 13:1240-1264, 1990
31. Yki-Jarvinen H: Drug therapy: thiazolidinediones. N Engl J Med 351:1106, 2004
32. Drucker DJ: Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nature Endocrinol Metab 1:22-31, 2005
33. Schmitz O, Brock B, Rungby J: Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 53 (Suppl. 3): S233-S238, 2004
34. Colagiuri S, Cull CA, Holman RR, UKPDS Group: Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? Diabetes Care 25:1410-1417, 2002
35. Harris MI: Epidemiologic correlates of NIDDM in Hispanics, whites and blacks in the U.S. population. Diabetes Care 14 (Suppl. 3):639-648, 1991
36. Rewers M, Hamman RF: Risk factors for non-insulin dependent diabetes. In Diabetes in America. 2nd ed. Harris M, Ed. Bethesda, MD, National Institutes of Health, 1995, p. 179-220 (NIH publ. no. 95-1468)
37. Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat HA, daRamon RA, Israel G, Dolezal JM: Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222:339-350, 1995
38. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larrson B, Narbro K, Sjostrom CD, Sullivan M, Wedel H, Swedish Obese Subjects Study Scientific Group: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351:2683-2693, 2004
39. Pontiroli AE, Folli F, Paganelli M, Micheletto G, Pizzocri P, Vedani P, Luisi F, Perego L, Morabito A, Doldi SB: Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity. Diabetes Care 28:2703-2709, 2005
40. Diabetes Prevention Program Research Group: Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care 28:888-894, 2005
41. Hadden DR, Montgomery DAD, Skelly RJ, Trimble ER, Weaver JA, Wilson EA, Buchanan KD: Maturity onset diabetes mellitus: response to intensive dietary management. BMJ 3:276-278, 1975
42. DeFronzo R, Goodman A, Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541, 1995
43. Salpeter S, Greyber E, Pasternak G, Salpeter E: Risk of fatal and nonfatal lactic acidosis with metfromin use in type 2 diabetes mellitus. Cochrane Database Syst Rev CD002967, 2006
44. Diabetes Prevention Program Research Group: Reduction in incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
45. Tessier D, Dawson K, Tetrault JP, Bravo G, Meneilly GS: Glibenclamide versus gliclazide in type 2 diabetes of the elderly. Diabet Med 11:974-980, 1994
46. Holstein A, Plaschke A, Egberts E-H: Lower incidence of severe hypoglycemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 17:467-473, 2001
47. Klimt CR, Knatterud GL, Meinert CL, Prout TE: The University Group Diabetes Program: a study of the effect of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. I. Design, methods and baseline characteristics. II. Mortality results. Diabetes 19 (Suppl. 2):747-830, 1970
48. Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, Hale PM: Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 27:1265-1270, 2004
49. Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron A: PRESERVE-β: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 28:2093-2100, 2005
50. Kristensen JS, Frandsen KB, Bayer T, Müller PG: Compared with repaglinide, sulfonylurea treatment in type 2 diabetes is associated with a 2.5 fold increase in symptomatic hypoglycemia with blood glucose levels <45 mg/dl (Abstract). Diabetes 49 (Suppl. 1):A131, 2000
51. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA 290:486-494, 2003
52. Khan MA, St. Peter JV, Xue JL: A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 25:708-711, 2002
53. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ, GLAI Study Investigators: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28:1547-1554, 2005
54. Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J, PROactive Investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomized controlled trial. Lancet 366:1279-1289, 2005
55. Himsworth HP, Kerr RB: Insulin-sensitive and insulin-insensitive types of diabetes mellitus. Clin Sci 4:119-152, 1939
56. Nathan DM, Roussell A, Godine JE: Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus: a randomized double-blind study. Ann Intern Med 108:334-340, 1988
57. Abraira C, Johnson N, Colwell J, VA CSDM Group: VA Cooperative study on glycemic control and complications in type II diabetes. Diabetes Care 18:1113-1123, 1995
58. Zammitt NN, Frier BM: Hypoglycemia in type 2 diabetes. Diabetes Care 28:2948-2961, 2005
59. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM: Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 161:1653-1659, 2005
60. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A: Initiating insulin therapy in type 2 diabetes. Diabetes Care 28:260-265, 2005
61. Dailey G, Rosenstock J, Moses RG, Ways K: Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 27:2363-2368, 2004
62. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, Chiasson J-L, Levin SR: Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes. Diabetes Care 27:256-2363, 2004
63. Rosenstock J, Zinman B, Murphy LJ, Clement SC, Moore P, Bowering CK, Hendler R, Lan S-P, Cefalu WT: Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes. Ann Intern Med 143:549-558, 2005
64. Cefalu WT, Skyler JS, Kourides IA, Landschulz WH, Balagtas CC, Cheng S-L, Gelfand RA, Inhaled Insulin Study Group: Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 134:203-207, 2001
65. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28:1083-1091, 2005
66. DeFronzo R, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092-1100, 2005
67. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, Exenatide-113 Clinical Study Group: Effects of exenatide on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27:2628-2635, 2004
68. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Intern Med 143:559-569, 2005
69. Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG: Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes. Diabetes Care 26:784-790, 2003
70. Welschen LMC, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, Stalman WAB, Bouter LM: Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. Diabetes Care 28:1510-1517, 2005
71. Hirsch IB, Bergenstal RM, Parkin CG, Wright E, Buse JB: A real-world approach to insulin therapy in primary care practice. Clin Diabetes 23:78-86, 2005
72. Schwartz S, Sievers R, Strange P, Lyness WH, Hollander P: Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs. Diabetes Care 26:2238-2243, 2003
73. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M: Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. Ann Intern Med 130:389-396, 1999
74. Strowig S, Aviles-Santa ML, Raskin P: Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care 27:1577-1583, 2004
75. Fonseca V, Rosenstock J, Patwardhan R, Salzman A: Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. JAMA 283:1695-1702, 2000
76. Bailey CJ, Bagdonas A, Rubes J, McMorn SO, Donaldson J, Biswas N, Stewart MW: Rosiglitazone/metformin fixed dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24 week, multicenter, randomized, double blind, parallel group study. Clin Ther 27:1548-1561, 2005